<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02686346</url>
  </required_header>
  <id_info>
    <org_study_id>BV-ICE</org_study_id>
    <nct_id>NCT02686346</nct_id>
  </id_info>
  <brief_title>Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE</brief_title>
  <acronym>BV-ICE</acronym>
  <official_title>Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a phase Ib/II trial. The first part (phase Ib) is a dose escalation
      design to explore the safety and assess the recommended phase 2 dose of Brentuximab Vedotin
      in Hodgkin lymphoma patients treated with ICE regimen.

      The second part, depending on the selected dose after the completion of phase Ib part of the
      study, will further explore safety in addition to efficacy of the recommended dose of
      Brentuximab Vedotin in a selected population of patients treated with ICE with Hodgkin
      lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PHASE I:

      3 cycles of Brentuximab Vedotin ICE every 3 weeks and one cycle of Brentuximab Vedotin alone
      at the doses described below.

      Cohorts of between three and six evaluable patients will be recruited at each dose level.

      Dose escalation rules:

      Treat 3 patients at level K

        1. If 0 patients experience dose-limiting toxicity (DLT), escalate to dose K+1

        2. If 2 or more patients experience DLT, de-escalate to level K-1

        3. If 1 patient experiences DLT, treat 3 more patients at dose level K A. If 1 of 6
           experiences DLT, escalate to dose level K+1 B. If 2 or more of 6 experiences DLT,
           de-escalate to level K-1 Dose escalation will begin at level K.

      Level K:

      Brentuximab Vedotin: 1.2 mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide
      100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2)

      Level K -1:

      Brentuximab Vedotin: 0.8 mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide
      100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2)

      Level K +1:

      Brentuximab Vedotin: 1.8 mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide
      100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2)

      Dose finding rule:

      Provisional dose levels are listed in previous tables. Dose-escalation will continue until
      Maximal Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D) is reached or the full doses
      of BV and ICE are delivered without DLT

      PHASE II:

      3 cycles of Brentuximab Vedotin + ICE every 3 weeks and one cycle Brentuximab Vedotin alone.

      The recommended dose of BV and ICE will be determined by the phase I Brentuximab Vedotin: MTD
      mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3);
      Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2) The recommended dose of BV
      and ICE will be determined by the phase I.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I : Maximal Tolerated Dose (MTD) determination</measure>
    <time_frame>4 months</time_frame>
    <description>To determine the MTD and/or Recommended Phase II dose (RP2D dose) of BV when administered to adult patients treated with ICE in refractory or relapsed Hodgkin's lymphomas.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II = fraction of responding patients according to Lugano classification (metabolic Complete Response)</measure>
    <time_frame>2 months</time_frame>
    <description>To evaluate the efficacy of BV in patient treated with ICE as first salvage treatment (establish the fraction of responding patients - metabolic Complete Response (CR)) as judged by the center by Lugano classification after the second cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I : Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>4 months</time_frame>
    <description>To characterize the safety and tolerability of BV in patient treated with ICE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I = Preliminary Overall Response Rate (ORR)</measure>
    <time_frame>4 months</time_frame>
    <description>To assess preliminary anti-tumor activity of BV in patient treated with ICE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = ORR</measure>
    <time_frame>4 months</time_frame>
    <description>To assess the ORR (Complete Response and Partial Response) after 3 cycles of BV and ICE and one cycle of BV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II : Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>4 months</time_frame>
    <description>To assess the toxicity profile of BV in patient treated with ICE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = number of patients with hematological recovery after each cycle</measure>
    <time_frame>4 months</time_frame>
    <description>To assess hematological recovery after each cycle of BV and ICE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Feasibility of Autologous Stem Cell Transplant (ASCT) after BV-ICE = fraction of patients for whom harvest is possible</measure>
    <time_frame>4 months</time_frame>
    <description>To assess the feasibility of harvesting an autologous peripheral blood stem cell graft after BV in patient treated with ICE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Fraction of patients eligible for ASCT</measure>
    <time_frame>4 months</time_frame>
    <description>To assess the fraction of patients (Complete Response/Partial Response) eligible for ASCT who actually underwent one or two ASCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Number of patients Positron Emission Tomography (PET) 4- after PET 2+</measure>
    <time_frame>4 months</time_frame>
    <description>To assess the number of patients with PET 4 negative if the PET 2 is positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Progression Free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants who did not progressed after 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II = Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants alive after 2 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>BV-ICE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I:
4 cycles of treatment, every 21 days: Brentuximab Vedotin (BV) + Etoposide- Carboplatine - Ifosfamide (ICE) = BV-ICE for cycles 1 to 3 and BV alone at cycle 4;
Phase II:
4 cycles of treatment, every 21 days: BV-ICE for cycles 1 to 3, BV alone at cycle 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <description>Phase I:
Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)
Phase II:
BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I</description>
    <arm_group_label>BV-ICE</arm_group_label>
    <other_name>BV</other_name>
    <other_name>SGN35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>100 mg/m² Days 1-2-3 of Cycles 1-2-3</description>
    <arm_group_label>BV-ICE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatine</intervention_name>
    <description>max 800mg Day 2 of Cycles 1-2-3</description>
    <arm_group_label>BV-ICE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>5 g/m² Day 2 of Cycles 1-2-3</description>
    <arm_group_label>BV-ICE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed cluster of differentiation antigen 30 + (CD30+) HL, primarily
             refractory to first line chemotherapy or in first relapse after any polychemotherapy
             regimen

          -  Measurable disease defined as at least one single node or tumor lesion on CT scan &gt;
             1.5 cm

          -  Fluorodeoxyglucose (FDG)-PET/ CT realized at relapse and positive.

          -  Age ≥ 18 years and up to 65 years

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2 (see appendix 19.5)

          -  Life expectancy of &gt; 3 months with treatment

          -  No major organ dysfunction, unless HL-related

          -  Normal cardiac and pulmonary function for auto transplantation

          -  Total bilirubin &lt; 1.5 x ULN (unless due to lymphoma involvement of the liver or a
             known history of Gilbert's syndrome)

          -  Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2 x ULN (unless due to
             lymphoma involvement of the liver : ≤ 5 x ULN)

          -  Creatinine clearance &gt; 60 mL/min

          -  Absolute neutrophil count ≥ 1.5x109/L, unless caused by diffuse bone marrow
             infiltration by the HL

          -  Platelets ≥ 100x109/L, unless caused by diffuse bone marrow infiltration by the HL

          -  Hemoglobin must be ≥ 8g/dL

          -  Written informed consent

          -  Able to adhere to the study visit schedule and other protocol requirements

          -  Eligible for high dose chemotherapy and autologous peripheral blood stem cell
             transplantation

          -  Resolution of toxicities from first-line therapy

          -  Female patient is either post-menopausal for at least 1 year before the screening
             visit or surgically sterile or if of childbearing potential, agree to practice 2
             effective methods of contraception, at the same time, from the time of signing the
             informed consent through 6 months after the last dose of study drug, or agrees to
             completely abstain from heterosexual intercourse.

          -  Male patients, even if surgically sterilized, (i.e., status post vasectomy) agree to
             practice effective barrier contraception during the entire study period and through 6
             months after the last dose of study drug, or agrees to completely abstain from
             heterosexual intercourse.

        Exclusion Criteria:

          -  Peripheral sensory or motor neuropathy grade ≥ 2

          -  Any chemotherapy, radiotherapy, immunotherapy or investigational, therapy for
             treatment of lymphoma within 28 days prior Cycle1 Day1

          -  Patient who have been treated by first line of treatment with brentuximab vedotin
             alone or in combination

          -  Female patients who are both lactating and breast feeding or have a positive serum
             pregnancy test during the screening period or a positive pregnancy test 4 days prior
             the start of study drug

          -  Patients with active, uncontrolled infections (requiring systemic antibiotics within
             two weeks prior to treatment)

          -  Prior history of another cancer unless the subject has been free of the disease for ≥
             3 years (with the exception of non-melanoma skin cancer, completely resected melanoma
             TNMpT1 or carcinoma in situ of the uterine cervix)

          -  Known cerebral or meningeal disease (HL or any other etiology), including signs or
             symptoms of Progressive multifocal leukoencephalopathy

          -  Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient
             contained in the drug formulation of brentuximab vedotin.

          -  Known history of human immunodeficiency virus (HIV), or known active Hepatitis C
             Virus, or active Hepatitis B Virus (HBV) infection or any uncontrolled active systemic
             infection requiring intravenous (IV) antibiotics.

          -  Patients with a psychiatric disorder that would preclude compliance with drug delivery

          -  Patients who have any severe and/or uncontrolled medical condition or other conditions
             that could affect their participation in the study such as:

               1. unstable angina pectoris, symptomatic congestive heart failure (NYHA II, III,
                  IV), myocardial infarction ≤ 2 years prior to first study drug administration,
                  serious uncontrolled cardiac arrhythmia, angina, or electrocardiographic evidence
                  of acute ischemia or active conduction system abnormalities

               2. cerebrovascular accident ≤ 6 months before study drug start recent evidence
                  (within 6 months before first dose of study drug)

               3. a left-ventricular ejection fraction &lt;50%

               4. severely impaired pulmonary function as defined as spirometry and diffusing
                  capacity of the lung for carbon monoxide (DLCO) that is 50% or less of the normal
                  predicted value and/or O2 saturation that is 90% or less at rest on room air

               5. any active (acute or chronic) or uncontrolled disorders that impair the ability
                  to evaluate the patient or for the patient to complete the study

               6. any active systemic viral, bacterial, or fungal infection requiring systemic
                  antibiotics within 2 weeks prior to first study drug dose

               7. nonmalignant medical illnesses that are uncontrolled or whose control may be
                  jeopardized by this study drug, such as severe hypertension that is not
                  controlled with medical management and thyroid abnormalities when thyroid
                  function cannot be maintained in the normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pauline Brice, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aspasia Stamatoullas Bastard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexia Schwartzmann</last_name>
    <email>alexia.schwartzmann@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Universitaire Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>CHU Dinant Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc ANDRE, MD</last_name>
      <phone>0032 81 42 38 64</phone>
      <email>marc.andre@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut d'Hématologie de Basse Normandie - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Claire GAC-BESNARD, MD</last_name>
      <phone>02 31 06 50 14</phone>
      <email>gac-ac@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP-Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien LE BRAS, MD</last_name>
      <phone>+33 1 49 81 43 20</phone>
      <email>fabien.le-bras@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Feriel BOUABBAS, CRA</last_name>
      <phone>+33 1 49 81 43 20</phone>
      <email>feriel.bouabbas@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon - Hôpital le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CASASNOVAS, MD</last_name>
      <phone>03 80 29 50 41</phone>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER, MD</last_name>
      <phone>03 20 44 60 68</phone>
      <email>f-morschhauser@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle NICOLAS-VIRELIZIER, MD</last_name>
      <phone>04 78 78 26 84</phone>
      <email>emmanuelle.nicolas@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe QUITTET, MD</last_name>
      <phone>03 67 33 83 66</phone>
      <email>p-quittet@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noémie COIGNART, CRA</last_name>
      <phone>04 67 33 24 54</phone>
      <email>n-coignart@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Véra SABADASH, CRA</last_name>
      <phone>04 67 33 24 54</phone>
      <email>v-sabadash@chu-montpellier.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe QUITTET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume CARTRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert NAVARO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yosr HICHRI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure VINCENT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU De Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GASTINNE, MD</last_name>
      <email>thomas.gastinne@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>PARIS Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armelle VILAIN, CRA</last_name>
      <phone>01 42 49 49 49</phone>
      <email>armelle.vilain@sls.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nadia HARROUCHE, CRA</last_name>
      <phone>01 42 49 49 49</phone>
      <email>nadia.hadouche@sls.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pauline BRICE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine THIEBLEMONT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie HAREL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandy AMORIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard DELARUE, MD</last_name>
      <phone>01 44 49 54 16</phone>
      <email>richard.delarue@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Haut-Lévêque - Centre François Magendie</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal-Krimo BOUABDALLAH, MD</last_name>
      <phone>05 57 65 65 11</phone>
      <email>krimo.bouabdallah@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre Bénite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie TRONCHON, MD</last_name>
      <email>virginie.tronchon@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles SALLES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand COIFFIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fadhela BOUFFIA-SAUVY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel ESPINOUSSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie MICHALLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure LEBRAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lionel KARLIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie BOUTELOUP, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel BACHY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers - Hôpital de La Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie GUIDEZ, MD</last_name>
      <phone>05 49 44 46 89</phone>
      <email>stephanie.guidez@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU De Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry LAMY DE LA CHAPELLE, MD</last_name>
      <phone>02 99 28 93 12</phone>
      <email>thierry.lamy.de.la.chapelle@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine ROBBE, CRA</last_name>
      <email>delphine.robbe@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Aspasia STAMATOULLAS - BASTARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oana BREHAR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice JARDIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane LEPRETRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hervé TILLY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal LENAIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie CONTENTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie LEMASLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Laure FONTOURA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole FRONVILLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie CARDINAEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène LANIC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ophélie CASSUTO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU De Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc-Mathieu FORNECKER, MD</last_name>
      <phone>03 88 12 76 67</phone>
      <email>luc-matthieu.fornecker@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCT Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile BOREL, MD</last_name>
      <phone>05 31 15 61 91</phone>
      <email>borel.cecile@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU De Nancy - Hôpital Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurore PERROT, MD</last_name>
      <phone>03 83 15 32 82</phone>
      <email>au.perrot@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>VILLEJUIF Cedex</city>
        <zip>94085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wassila RAHALI, CRA</last_name>
      <phone>01 42 11 66 08</phone>
      <email>wassila.rahali@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent RIBRAG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe FERME, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian BOURHIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David GHEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane DE BOTTOM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>WITTNEBEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MICOL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alina DANU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien LAZAROVICI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent RIBRAG</last_name>
      <phone>01 42 11 66 08</phone>
      <email>vincent.ribrag@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2016</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

